Navigation Links
Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
Date:2/24/2011

REDWOOD CITY, Calif., Feb. 24, 2011 /PRNewswire/ -- Pearl Therapeutics announced today the appointment of Chuck Bramlage to the position of president and chief executive officer. In addition, Mr. Bramlage will join the Company's Board of Directors. Both appointments were effective as of February 22, 2011.

"Chuck brings almost 30 years of pharmaceutical and biotechnology leadership experience to Pearl," said James W. Young, PhD, chairman of the Pearl Board of Directors and venture partner at 5AM Ventures. "His expertise in the respiratory space, familiarity with both biotechnology and pharmaceutical operations, and understanding of the global commercial landscape will be of critical importance as we advance development of our lead COPD program through a rigorous phase 2b clinical program and toward the market."

Mr. Bramlage previously held several executive positions at Covidien plc, most recently president of pharmaceutical products. Earlier, he served as president of European operations at Valeant Pharmaceuticals International and president and chief executive officer of BattellePharma, Inc., a specialty pharmaceutical company developing inhaled products. In addition, he was formerly the vice president of respiratory global commercial development and vice president of U.S. respiratory and cardiovascular marketing for GlaxoSmithKline, where he led the team responsible for the global launch of Seretide®/Advair® and the U.S. launch of Flovent®.

Dr. Young continued, "On behalf of the Board of Directors and management team at Pearl, I would like to thank Howard Rosen, who graciously took the helm as interim president and chief executive officer of Pearl while we conducted this search. We look forward to Howie's continued counsel as he returns to his former role as a member of the Pearl Board of Directors."

About Pearl Therapeutics

Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, as well as formulation and product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals therapies that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.


'/>"/>
SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Secures $8 Million in Debt Financing
2. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
3. Pearl Therapeutics Appoints Howie Rosen to Board of Directors
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
9. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
10. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
11. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, was today awarded ... The awards program is based entirely on merit and decided upon by a ...
(Date:1/19/2017)... 18, 2017 Acupath Laboratories, Inc., a leading ... of an Executive Committee that will guide the company,s ... John Cucci , a 15-year veteran of the ... Business Development to Chief Sales Officer .  Prior ... in senior sales leadership roles at several leading lab ...
(Date:1/18/2017)... 2017 Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced that Dr. ... of Applied BioMath, will present at the next ... Meeting on Thursday January 19, 2017 at the ... MA.   Dr. Burke,s talk "Quantitative Modeling and Simulation ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker ... Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the award of a ...
Breaking Biology Technology:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):